📊 LRMR Key Takeaways
Is Larimar Therapeutics, Inc. (LRMR) a Good Investment?
Larimar Therapeutics is a pre-revenue biopharmaceutical company with zero commercial sales and rapidly deteriorating financials. With annual operating losses of $172.5M and operating cash burn of $113.2M against only $85.4M in cash reserves, the company has approximately 9 months of runway at current burn rates and faces imminent financing pressure. The combination of pre-commercialization status, mounting losses, and high cash consumption with no visible path to profitability represents material fundamental weakness.
Larimar is pre-revenue with sharply negative and worsening profitability, including a -$113M operating cash outflow that exceeds its $85M cash balance, implying a short runway and high financing dependence. While leverage is modest and liquidity is acceptable, the absence of revenue and severely negative returns indicate weak near-term fundamentals.
Why Buy Larimar Therapeutics, Inc. Stock? LRMR Key Strengths
- Strong current cash position of $85.4M provides near-term operational runway
- Low financial leverage with Debt/Equity ratio of 0.19x and minimal long-term debt burden
- Healthy liquidity ratios (2.19x current ratio) provide short-term financial flexibility
- Adequate liquidity with 2.19x current/quick ratio
- Low leverage (0.19x D/E; $14.5M long-term debt)
- Minimal capex requirements (asset-light)
LRMR Stock Risks: Larimar Therapeutics, Inc. Investment Risks
- Zero revenue with no demonstrated commercial success or market traction
- Accelerating cash burn of $113.2M annually against limited cash reserves creates funding urgency
- Pre-revenue biopharmaceutical company entirely dependent on uncertain clinical trial outcomes and regulatory approval
- Deteriorating profitability with net income declining 105.5% year-over-year indicating worsening operations
- Negative returns (ROE -212.2%, ROA -113.6%) demonstrate capital destruction at current operational level
- Sustained and rising operating losses and negative FCF (-$113M)
- Short cash runway likely requiring dilutive or costly financing
- Severely negative ROE/ROA and interest coverage
Key Metrics to Watch
- Cash burn rate and months of cash runway remaining
- Clinical trial progress and pipeline advancement timelines
- Financing announcements and capital raise terms
- Quarterly operating cash flow trends
- Operating cash flow and quarterly burn rate
- Cash and equivalents vs. forecast runway
Larimar Therapeutics, Inc. (LRMR) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.19x current ratio provides a solid financial cushion.
LRMR Profit Margin, ROE & Profitability Analysis
LRMR vs Healthcare Sector: How Larimar Therapeutics, Inc. Compares
How Larimar Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Larimar Therapeutics, Inc. Stock Overvalued? LRMR Valuation Analysis 2026
Based on fundamental analysis, Larimar Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Larimar Therapeutics, Inc. Balance Sheet: LRMR Debt, Cash & Liquidity
LRMR Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Larimar Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.84 indicates the company is currently unprofitable.
LRMR Revenue Growth, EPS Growth & YoY Performance
LRMR Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2020 | N/A | -$3.6M | N/A |
| Q3 2019 | N/A | -$12.1M | N/A |
| Q2 2019 | N/A | -$12.1M | N/A |
| Q1 2019 | N/A | -$13.1M | N/A |
| Q3 2018 | N/A | -$12.6M | N/A |
| Q2 2018 | N/A | -$13.3M | N/A |
| Q1 2018 | N/A | -$13.0M | N/A |
| Q3 2017 | N/A | -$12.6M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Larimar Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
LRMR SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Larimar Therapeutics, Inc. (CIK: 0001374690)
📋 Recent SEC Filings
❓ Frequently Asked Questions about LRMR
What is the AI rating for LRMR?
Larimar Therapeutics, Inc. (LRMR) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 75% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are LRMR's key strengths?
Claude: Strong current cash position of $85.4M provides near-term operational runway. Low financial leverage with Debt/Equity ratio of 0.19x and minimal long-term debt burden. ChatGPT: Adequate liquidity with 2.19x current/quick ratio. Low leverage (0.19x D/E; $14.5M long-term debt).
What are the risks of investing in LRMR?
Claude: Zero revenue with no demonstrated commercial success or market traction. Accelerating cash burn of $113.2M annually against limited cash reserves creates funding urgency. ChatGPT: Sustained and rising operating losses and negative FCF (-$113M). Short cash runway likely requiring dilutive or costly financing.
What is LRMR's revenue and growth?
Larimar Therapeutics, Inc. reported revenue of $0.0.
Does LRMR pay dividends?
Larimar Therapeutics, Inc. does not currently pay dividends.
Where can I find LRMR SEC filings?
Official SEC filings for Larimar Therapeutics, Inc. (CIK: 0001374690) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is LRMR's EPS?
Larimar Therapeutics, Inc. has a diluted EPS of $-1.50.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is LRMR a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Larimar Therapeutics, Inc. has a SELL rating with 75% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is LRMR stock overvalued or undervalued?
Valuation metrics for LRMR: ROE of -212.2% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy LRMR stock in 2026?
Our dual AI analysis gives Larimar Therapeutics, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is LRMR's free cash flow?
Larimar Therapeutics, Inc.'s operating cash flow is $-113.2M, with capital expenditures of $91.0K.
How does LRMR compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -212.2% (avg: 15%), current ratio 2.19 (avg: 2).